KPV: Published Research

Introduction

KPV (Lys-Pro-Val; α-MSH positions 11–13) has been the subject of published preclinical research since the early 2000s, with study designs ranging from in vitro receptor binding assays and cell-culture inflammatory models to murine in vivo experiments. This article provides a bibliographic summary of identified peer-reviewed studies. All findings are attributed to their source publications. The evidence base is preclinical — no clinical trials involving KPV as a primary investigational agent are listed in publicly available registries — placing the compound at an active early-research stage with the foundational pharmacology well characterized.

Methodology Types

The published literature on KPV spans several experimental methodologies. Receptor pharmacology studies have used radioligand binding displacement assays and intracellular cAMP quantification to characterize KPV's interaction profile with melanocortin receptor subtypes. Cell culture experiments have employed human bronchial epithelial cell lines, intestinal epithelial cell lines (including Caco-2 and HT-29), murine macrophage cultures (RAW 264.7), and murine microglial cultures to assess KPV's effects on NF-κB activation, cytokine secretion, and inflammatory signal transduction. Animal model experiments have primarily used murine models of experimentally induced inflammation: crystal-induced peritonitis, dextran sodium sulfate (DSS)- and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced intestinal inflammation, and weight-drop controlled cortical impact (CCI) traumatic brain injury.

Summary of Studies

Getting, Schiöth, and Perretti (2003) — Peritonitis Model, Receptor Dissection

Getting and colleagues published the foundational pharmacological dissection study in the Journal of Pharmacology and Experimental Therapeutics [1]. Using a murine model of crystal-induced peritonitis, the authors compared the anti-inflammatory effects of intact α-MSH, synthetic core-pharmacophore melanocortin agonists (MTII), and the C-terminal tripeptide KPV. The study reported that systemic administration of KPV was associated with a statistically significant reduction in polymorphonuclear leukocyte accumulation in the peritoneal cavity. The finding that KPV's effect was not blocked by a melanocortin MC3/MC4 receptor antagonist established mechanistic independence from canonical melanocortin receptor pharmacology and pointed toward IL-1β pathway interference as the operative mechanism. This study shaped the subsequent research agenda for KPV, with the molecular basis of that receptor-independent signaling detailed in the KPV mechanism of action article.

Dalmasso, Charrier-Hisamuddin, Nguyen, Yan, Sitaraman, and Merlin (2008) — PepT1-Mediated Uptake

Dalmasso and colleagues published in Gastroenterology a study examining how KPV enters epithelial cells and the downstream effects of that uptake [2]. The study demonstrated that KPV is a substrate for PepT1 (SLC15A1), the proton-coupled oligopeptide transporter expressed in small intestinal epithelium. In intestinal epithelial cell lines, nanomolar concentrations of KPV were reported to inhibit NF-κB and MAP kinase inflammatory signaling pathways and reduce secretion of pro-inflammatory cytokines. The identification of PepT1 as a cellular uptake transporter for KPV provided a plausible intracellular delivery mechanism — particularly relevant because PepT1 normally handles dietary di- and tripeptides — and opened a research direction that subsequent groups extended with nanoparticle delivery strategies.

Kannengiesser, Maaser, Heidemann, et al. (2008) — Murine Experimental Inflammation Models

Kannengiesser and colleagues published in Inflammatory Bowel Diseases a study examining KPV in two well-characterized murine experimental inflammation models using DSS-induced and TNBS-induced protocols [3]. The authors reported that KPV administration was associated with reduced clinical disease activity index scores, improved macroscopic colon appearance, reduced mucosal inflammatory infiltrate on histological examination, and lower expression levels of pro-inflammatory cytokines compared with vehicle-treated controls. The findings complemented the Dalmasso et al. paper by confirming the tripeptide's modulation of intestinal inflammatory readouts in a separate laboratory and experimental design.

Land (2012) — Bronchial Epithelium, Importin-α Mechanism

Land published in the International Journal of Physiology, Pathophysiology and Pharmacology the most detailed mechanistic characterization of KPV to date [4]. Working in human bronchial epithelial cells stimulated with TNF-α, the author used co-immunoprecipitation and GST pull-down assays to show that KPV translocated to the nucleus and competitively blocked the interaction between importin-α3 and the nuclear localization signal of p65RelA, preventing p65RelA nuclear import without affecting upstream IκBα phosphorylation. Downstream inflammatory readouts — including IL-8, eotaxin, and MMP-9 — showed dose-dependent reductions. The study also identified a complementary role for MC3R agonism in the same epithelial system, suggesting that the receptor-independent NLS blockade pathway and the MC3R-mediated cAMP pathway may converge on overlapping inflammatory targets.

Schaible, Steinsträßer, Jahn-Eimermacher, et al. (2013) — Traumatic Brain Injury Model

Schaible and colleagues published in PLoS One a study examining the effects of a single administration of α-MSH(11–13) — the tripeptide sequence equivalent to KPV — in a murine controlled cortical impact (CCI) model of traumatic brain injury [5]. At 24 hours post-injury, the treated group was reported to show a secondary lesion volume approximately 24% smaller than vehicle controls, reduced neuronal apoptosis as measured by TUNEL staining, and attenuated microglial branch complexity in the peri-lesion region. In vitro experiments with murine microglial cells showed that KPV was associated with reductions in TNF-α, IL-6, and nitric oxide production following lipopolysaccharide stimulation. The authors noted that the tripeptide lacked the melanotropic side-effects associated with full-length α-MSH, attributed to the absence of the core His-Phe-Arg-Trp pharmacophore — a finding relevant to KPV's research profile as a receptor-independent agent.

Xiao, Xu, Viennois, et al. (2017) — Nanoparticle Delivery

Xiao and colleagues published in Molecular Therapy a study exploring targeted delivery of KPV via hyaluronic acid-functionalized polymeric nanoparticles in murine experimental models [6]. KPV was encapsulated in HA-functionalized nanoparticles (HA-KPV-NPs) approximately 272 nm in diameter. When incorporated into an oral chitosan/alginate hydrogel formulation, the nanoparticles preferentially delivered KPV to colonic epithelial cells and macrophages — cell populations expressing the hyaluronic acid receptor CD44, upregulated in inflamed colonic tissue. The study reported macroscopic and histological improvements compared with controls. This work extended the Dalmasso PepT1 findings by demonstrating that nanoparticulate encapsulation provides an additional delivery vehicle for KPV independent of transporter-mediated uptake.

Songok, Panta, Doerrler, Macnaughtan, and Taylor (2018) — Lysine Modification Chemistry

Songok and colleagues published in PLoS One a synthetic chemistry study examining glycoalkylation — reductive alkylation of the lysine ε-amine with a glucose-derived aldehyde — as a modification strategy for KPV [7]. The glycoalkylated derivatives demonstrated resistance to pronase-mediated proteolysis compared with the unmodified tripeptide, establishing the feasibility of producing metabolically stable KPV analogues through lysine-targeted chemistry. This study is cited in the structural modification literature as a foundation for future analogue programs targeting improved pharmacokinetic stability.

Active Research Frontier

The KPV research literature is at an early and active stage. Pharmacokinetic characterization — including plasma half-life, distribution volume, and tissue penetration — represents a direction that systematic investigation is positioned to address. The relative contributions of the importin-α blockade mechanism (described in bronchial epithelial cells) and the PepT1-mediated intracellular delivery pathway (described in intestinal epithelial cells) to KPV's profile across other tissue types is an open question informing current research design. The structural requirements for KPV's biological activity have not yet been fully mapped at residue resolution, and whether the proteolysis-resistant glycoalkylated analogues produced by Songok et al. (2018) retain the anti-inflammatory profile of the parent tripeptide is among the questions that the analogue program will address. Each of these directions represents an opportunity for the next generation of KPV research. The melanocortin receptor-targeted program running in parallel — represented by compounds such as PT-141 — offers a point of comparison for how receptor-dependent and receptor-independent branches of α-MSH pharmacology have diverged in research focus. Research-grade KPV from SpartaLabs is available with full COA documentation for investigators extending this work.

References

1. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. PMID: 12750433. DOI: 10.1124/jpet.103.051623

2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177. DOI: 10.1053/j.gastro.2007.10.026

3. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 18092346. DOI: 10.1002/ibd.20334

4. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID: 22837805

5. Schaible EV, Steinsträßer A, Jahn-Eimermacher A, Luh C, Sebastiani A, Kornes F, Pieter D, Schäfer MK, Engelhard K, Thal SC. Single Administration of Tripeptide α-MSH(11–13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice. PLoS One. 2013;8(8):e71056. PMID: 23940690. DOI: 10.1371/journal.pone.0071056

6. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. PMID: 28143741. DOI: 10.1016/j.ymthe.2016.11.020

7. Songok AC, Panta P, Doerrler WT, Macnaughtan MA, Taylor CM. Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue. PLoS One. 2018;13(6):e0199686. PMID: 29953505. DOI: 10.1371/journal.pone.0199686